Zevra Therapeutics ZVRA
NASDAQ ZVRA
$11.85 -0.07 (-0.59%)
At close: Nov 11, 2026 · 4:00 PM EST

Zevra Therapeutics (ZVRA) Cash from Restructuring (2023)

Updated

Zevra Therapeutics' Cash from Restructuring was $354,000 in Q1 2023.

Analysis

Zevra Therapeutics (ZVRA) Cash from Restructuring (2023) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Zevra Therapeutics 708.52 Mn -100.24 Mn 36.01 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2023 354,000.00
API Access

Zevra Therapeutics Cash from Restructuring API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-restructuring&ticker=ZVRA&period=max&api_key=YOUR_API_KEY